Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulva.
Fabinshy ThangarajahBernd MorgensternCaroline PahmeyerLars Mortimer SchiffmannJulian PuppePeter MallmannStefanie HamacherReinhard BuettnerChristina AlidoustyBarbara HolzAndreas H ScheelAnne Maria SchultheisPublished in: Journal of cancer research and clinical oncology (2019)
The present study showed that a relevant amount of patients with squamous cell cancer of the vulva express PD-L1 in both, tumour cells and tumour-associated immune cells. Furthermore, the significant correlation of PD-L1 expression in TCs with tumour stage indicated the clinical impact of PD-L1 expression during tumour development. These data indicate that SQCV might be amenable to immune checkpoint-inhibition and constitute a rational for the future clinical trials.
Keyphrases
- squamous cell
- clinical trial
- induced apoptosis
- poor prognosis
- randomized controlled trial
- cell cycle arrest
- electronic health record
- squamous cell carcinoma
- papillary thyroid
- big data
- binding protein
- long non coding rna
- deep learning
- cell proliferation
- phase ii
- current status
- artificial intelligence
- young adults
- open label
- data analysis
- lymph node metastasis
- pi k akt